UBS Group
DMRA

UBS Group’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

UBS Group’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.15M Buy
160,415
+154,026
+2,411% +$3.96M ﹤0.01% 4263
2025
Q4 		$147K Buy
6,389
+6,330
+10,729% +$110K ﹤0.01% 6730
2025
Q3 		$220 Sell
59
-2,254
-97% -$7.63K ﹤0.01% 9800
2025
Q2 		$7.89K Buy
2,313
+2,028
+712% +$6K ﹤0.01% 8994
2025
Q1 		$883 Sell
285
-12,182
-98% -$57.4K ﹤0.01% 9630
2024
Q4 		$58K Buy
12,467
+7,368
+144% +$48.2K ﹤0.01% 7208
2024
Q3 		$62K Buy
+5,099
New +$66.5K ﹤0.01% 6681
2024
Q1 		– Sell
-171
Closed -$3.08K – 9581
2023
Q4 		$3.08K Sell
171
-113
-40% -$1.74K ﹤0.01% 8009
2023
Q3 		$5.1K Buy
+284
New +$11.2K ﹤0.01% 7391
2023
Q2 		– Sell
-99
Closed -$4.94K – 9172
2023
Q1 		$4.94K Buy
+99
New +$5.22K ﹤0.01% 8114
2022
Q4 		– Sell
-164
Closed -$8K – 10866
2022
Q3 		$8K Buy
+164
New +$8.32K ﹤0.01% 8713
2022
Q2 		– Sell
-100
Closed -$5K – 10545
2022
Q1 		$5K Sell
100
-170
-63% -$9.55K ﹤0.01% 9125
2021
Q4 		$20K Buy
+270
New +$21.2K ﹤0.01% 7838
2021
Q3 		– Sell
-313
Closed -$40K – 9743
2021
Q2 		$40K Buy
+313
New +$42.6K ﹤0.01% 6631

Other funds holding DMRA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCP
Remedium Capital Partners Fort Lauderdale, Florida $281M AUM

UBS Group's DMRA Position: Q1 2026 in Review

UBS Group increased its Damora Therapeutics, Inc. Ordinary Shares (DMRA) stake by 2,411% in Q1 2026, buying an estimated $3.96M and bringing the position to 160,415 shares worth $4.15M. The position accounts for ﹤0.01% of the portfolio, ranked #4263.

UBS Group first reported a position in DMRA in Q2 2021 and has held it in 14 quarters since. 65 funds tracked by Wall St. Rank hold DMRA as of Q1 2026.

  • UBS Group held 160,415 shares of Damora Therapeutics, Inc. Ordinary Shares worth $4.15M as of Q1 2026.
  • UBS Group bought 154,026 Damora Therapeutics, Inc. Ordinary Shares shares in Q1 2026, an estimated $3.96M.
  • Damora Therapeutics, Inc. Ordinary Shares made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #4263 holding.
  • UBS Group first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q2 2021 and has held it in 14 quarters since.
  • 65 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.